MOTS-c Acetate Injection
Product Overview
MOTS-c (mitochondrial open reading frame of the twelve S rRNA-c) Acetate is a small peptide made from instructions found in mitochondria, the energy-producing part of cells.[1] MOTS-c has been studied primarily in animal and laboratory models for its possible role in metabolism, insulin sensitivity, and energy use. Animal and lab studies suggest that MOTS-c may influence how the body processes glucose and how mitochondria function.[1,2]
Most of the available evidence for MOTS-c comes from animal and laboratory studies; very limited human data exists. MOTS-c Acetate is not approved by the U.S. Food and Drug Administration for any indication.
Use should be guided by a licensed healthcare provider with consideration of the available evidence.
The information below reflects a commonly used dosing approach for this product. It is provided for general information only and is not a dosing recommendation. A prescribing provider may select a different amount, frequency, or duration based on the patient’s treatment goals, response, tolerability, medical history, concomitant therapies, and other patient-specific factors.
Inject 0.5 to 1 mg subcutaneously daily or up to five times weekly in cycles of 4 weeks on, 4 weeks off.
Your prescribed amount, strength, frequency, or duration may differ from the common dosing information shown above. Use this medication only as directed on your prescription label, and do not change how you use it unless instructed by your prescribing provider. Contact your provider or pharmacist if you have questions about your individualized directions.
MOTS-c Acetate is believed to exert its effects through modulation of metabolic signaling pathways and mitochondrial-nuclear communication.[1,2]
Proposed mechanisms include:
Regulation of glucose metabolism: Has been shown to enhance glucose uptake and improve insulin sensitivity in experimental models[1]
- Activation of AMP-activated protein kinase (AMPK): The peptide may activate AMPK pathways, which play a central role in energy homeostasis and cellular metabolism[1]
- Mitochondrial-nuclear signaling: Translocates to the nucleus under metabolic stress conditions, where it may regulate gene expression related to metabolism and stress response[2]
- Adaptation to metabolic stress: Experimental data suggest that it may support cellular adaptation to metabolic challenges, including oxidative stress[1]
These mechanisms are primarily supported by preclinical studies. The clinical relevance of these findings in humans remains under investigation.
Due to limited human data, MOTS-c Acetate should be used with caution.
- Long-term human exposure and safety data has not been established
- Avoid use in patients with active malignancy
- May pose risk for immunogenicity for certain routes of administration and may have complexities regarding peptide-related impurities[3]
- MOTS-c is listed as a prohibited substance by the World Anti-Doping Agency; athletes subject to anti-doping testing should be counseled accordingly[4]
Therapy should be individualized and supervised by a qualified healthcare provider.
Formal drug interaction studies have not been conducted.
Potential interactions may include:
- Medications affecting glucose metabolism
- Agents influencing mitochondrial function or energy metabolism
- Metabolic therapies targeting AMPK or related pathways
Patients should disclose all medications and supplements prior to initiation.
Clinical safety data for MOTS-c Acetate in humans are limited.
Based on available data and mechanism of action, potential side effects may include:
- Injection site reactions (pain, redness, or irritation)
- Headache
- Fatigue
- Nausea
The full safety profile in humans has not been established.
Any suspected side effects, medication errors, and concerns about this medication, such as the wrong strength, possible contamination, or problems with labeling or packaging, should be reported to the prescribing healthcare provider, Empower Pharmacy, and the FDA through MedWatch. For this compounded medication, reports should also be submitted to the appropriate state regulatory authority where the product was compounded and the state where it was shipped, if different.
MOTS-c Acetate has not been adequately studied in pregnant or breastfeeding individuals.
Due to limited safety data and its role in metabolic and cellular signaling pathways, use during pregnancy and breastfeeding is contraindicated.
Proper storage of MOTS-c Acetate injections is important to maintain stability and consistency.
- Storage: Refrigerated (36°F to 46°F (2°C to 8°C))
Do not use beyond the beyond-use date provided by Empower.
Disclaimer
Compounded products are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. Compounded products from our 503A facility are available only through a valid patient-specific prescription from a licensed prescriber and are prepared by a licensed pharmacy; shipping and state restrictions may apply. Compounded drug products from our 503B facility are only available for order by licensed healthcare providers and pharmacies. This document is for educational and informational use by healthcare professionals. It is not medical, legal, or regulatory advice, and it is not a promotion of any product. Except for products identified as currently available, it is not a statement of product availability.
Regulatory status
HHS’s interim policy is an expression of enforcement intent under stated conditions; it does not approve any product, change the requirements of the FD&C Act, or place any substance on the 503A Bulks List, which requires FDA rulemaking. PCAC recommendations are advisory. No dose of this product has been established as safe or effective in humans. State boards of pharmacy and medicine independently regulate compounding and prescribing. Regulatory status can change; confirm current status with FDA, HHS, and applicable state authorities before relying on this summary.
Reporting
Healthcare professionals and patients are encouraged to report suspected adverse events and product quality concerns to FDA MedWatch (fda.gov/medwatch; 1-800-FDA-1088).
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516-524.e7. doi:10.1016/j.cmet.2018.06.008.
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. FDA. Updated April 22, 2026. Accessed November 5, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- World Anti-Doping Agency. International standard prohibited list 2026. Published September 24, 2025. Accessed November 5, 2026.
What Is the HHS Peptide Enforcement Discretion Policy?
HHS’s peptide enforcement discretion policy is a statement that it does not intend to take enforcement action against certain peptide compounding when specific conditions are met. It is a draft interim policy that is not binding on HHS or the public, and it does not change Section 503A. The policy stays in place while FDA builds the 503A bulk drug substances list through rulemaking. It applies to state-licensed pharmacies, Federal facilities, and licensed physicians. A “licensed physician” here means one who compounds, not prescribers in general.
For prescribers, this changes the federal enforcement picture for the pharmacies you can work with, but it does not impact any state-specific laws or regulations that may exist in your state.
Which Peptides Does the Policy Cover?
Six: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. Each is limited to the specific form and routes listed. A peptide not on the list, or in a different form or route, is outside the policy.
Source: Appendix B of the HHS policy. Appendix B defines each peptide by exact sequence and formula. For instance, it describes TB-500 as a fragment of its parent protein, thymosin beta-4. The full text is in the Federal Register notice.
Do Prescribers Need a Patient-Specific Prescription?
Yes. The policy names section 503A’s patient-specific prescription requirement as one of its conditions The clinical decision for each patient is still yours. Consider documenting:
- Your clinical rationale for each individual patient
- Patient consent, including that the product is compounded and not FDA-approved
- The specific peptide, form, and route, checked against Appendix B
Is a Compounded Peptide FDA-Approved?
No. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed. None of these six peptides is an FDA-approved drug.
HHS states that its policy is meant to expand patient access while FDA reviews these substances. Enforcement discretion describes how HHS intends to use its enforcement resources. It is not an approval of any peptide or compounded product.
Where did the active ingredient come from?
An FDA-registered original manufacturer, with a Certificate of Analysis reviewed for each lot.
Can I see testing, not just a purity number?
Each batch is released with a Certificate of Conformance. Prescribers can request it.
What is a COC, and what is a COA?
A Certificate of Conformance (COC) is Empower’s batch-release document for a finished peptide; prescribers can request it. A Certificate of Analysis (COA) comes from the active ingredient manufacturer for each lot and, as reported, must show the manufacturer’s location under the HHS policy. Confirm details in the policy text.
Related medications
503A vs 503B
- 503A pharmacies compound products for specific patients whose prescriptions are sent by their healthcare provider.
- 503B outsourcing facilities compound products on a larger scale (bulk amounts) for healthcare providers to have on hand and administer to patients in their offices.
Frequently asked questions
Our team of experts has the answers you're looking for.
A clinical pharmacist cannot recommend a specific doctor. Because we are licensed in all 50 states*, we can accept prescriptions from many licensed prescribers if the prescription is written within their scope of practice and with a valid patient-practitioner relationship.
*Licensing is subject to change.
Each injectable IV product will have the osmolarity listed on the label located on the vial.

Given the vastness and uniqueness of individualized compounded formulations, it is impossible to list every potential compound we offer. To inquire if we currently carry or can compound your prescription, please fill out the form located on our Contact page or call us at (877) 562-8577.
We source all our medications and active pharmaceutical ingredients from FDA-registered suppliers and manufacturers.

Wolverine Stack
Glow Stack
Klow Stack
NAD+ Injection (Aqueous)
NAD+ Nasal Spray
Rapamycin (Sirolimus) Capsules
Semaglutide / Cyanocobalamin Injection
Semaglutide / Methylcobalamin ODT
Tirzepatide / Niacinamide Injection
Tirzepatide ODT
Sermorelin Acetate Injection
Sermorelin Acetate ODT
Lipo-B Injection
Lipo-C Injection